Kevan R. Polkinghorne

Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial

Abstract Background Polypharmacy in chronic kidney disease (CKD) is substantial. Clinicians and patients are often reluctant to add medications to already complex regimens, partly due to concerns about diminishing efficacy and increased adverse effects. We assessed whether effica...